Panel talk about Inify’s second quarter 2024

"We are saving weeks in waiting time for patients to get the diagnosis". 
This and more value that Inify Laboratories can provide to its customers from day one is highlighted in this panel talk about the second quarter of 2024 with CEO Fredrik Palm, Laboratory Director Emelie Edvigsson and Ole Eikeland.

Inify Laboratories continued to deliver strong growth with sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients.

More details about the laboratory operations and its success factors are discussed in a panel talk led by Ole Eikeland with Inify's CEO Fredrik Palm and Laboratory Director Emelie Edvigsson. 

Link to the panel talk is available here.  
 
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by Inify's own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.

Tags: